Epilepsy With Myoclonic Atonic Seizures Therapeutics Market
Epilepsy With Myoclonic Atonic Seizures Therapeutics Market
Segments - Epilepsy with Myoclonic Atonic Seizures Therapeutics Market by Drug (Sodium Valproate and Levetiracetam), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2024–2032
Upcoming
| Report ID :HC-6229
| 3.6 Rating
| 46 Reviews
| 260 Pages
| Format :
Report Description
Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Outlook 2032
The global epilepsy with myoclonic atonic seizures therapeutics market size was USD 50.2 Million in 2023 and is projected to reach USD 70.2 Million by 2032, expanding at a CAGR of 3.8% during 2024–2032. The market growth is attributed to the rising prevalence of epilepsy with myoclonic atonic seizures and increasing number of diagnostic methods. Furthermore, the growing awareness of disease and advanced studies in neurobiological science is driving the epilepsy with myoclonic atonic seizures therapeutics market.
Epilepsy with myoclonic atonic seizures (EMAS) is considered as a primary epilepsy, in the same family succession as the juvenile myoclonic and absence epilepsies. Neuropediatric Department, University of Kiel, Germany states that 32% of the probands suffer from epilepsy with myoclonic atonic seizures within a positive family history. EMAS is a result of multifactorial inheritance and a broad phenotype of EMAS is the final result of this inheritance.
- On November 14, 2020, according to a study published by Epilepsia journal, 166 children with epilepsy found global developmental delay in 2% at onset and 49% during the disease. Afebrile seizures occurred in 88%, followed by generalized tonic-clonic seizures in 60%, and drop attack seizures in 30%. Electroencephalography showed 28% normal at onset, with subsequent slowing and seizures in 90%. Response to antiseizure drugs was 26%, with diet therapy being used in 57%. Seizure freedom occurred in 57%, with normal development in 47%.
International League Against Epilepsy (ILAE) describes EMAS by a normal development and cognition between 6 months and 6 years prior to seizure, followed by the outcomes of it which occurs after seizure onset. However, study shows that, 21% of patients have a developmental delay before the onset of epilepsy.
-
In 2018, a survey conducted by Divisions of Pediatric Neurology and Epilepsy, Department of Neurology, Mayo Clinic, the US, the available diagnosis and treatment for EMAS showed only 50% to 79% developmental delay before the onset of seizure and became an exclusive criterion for the diagnosis of EMAS.
EMAS, also known as Doose syndrome, is involved in sudden muscle loss with myoclonic jerks (brief muscle contractions). The combinations of these two symptoms leads to involuntary collapse.
Therapeutics often includes the usage of antiepileptic medications for controlling seizures. Additionally, there are medications which are under the clinical trials or waiting for the approvals. As reported on February 16, 2024, drugs such as, Vatiquinone, NPT-2042 by NeuroPro Therapeutics, and Zorevunersen Sodium by Stoke Therapeutics are in likelihood for approval in the coming years.
Impact of Artificial Intelligence (AI) in the Epilepsy with Myoclonic Atonic Seizures Therapeutics Market
Artificial Intelligence impact epilepsy with myoclonic atonic seizures therapeutics market with its emerging opportunities. The Artificial Intelligence helps the drugs to set its target. Using the AI the targeted site is found, which leads to the precise drug discovery. Moreover, the precision medicine derives the personalized form of therapy which depends on the individual signs and symptoms.
Telemedicine, in the world of healthcare, is revolutionizing the method of prescription and drug supply to an individual. The epilepsy with myoclonic atonic seizures therapeutics market is expected to drive significantly during the forecast period, due to increasing use of telemedicine. Machine learning algorithms are expected to enable the generation of an automated response to a new set of data by combining the statistics and yield new drugs in the coming years.
Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Dynamics
Major Drivers
Rising patient population suffering from epilepsy with myoclonic atonic seizures and growing awareness among the population for the disease are driving the market. Previously, around three-fourth of the population in low-income nations were unable to receive the treatment, due to lack of awareness.
Increasing government initiatives for the low-cost medicines is expected to fuel the market exponentially during the forecast period. Additionally, the rising government funding for the clinical activities is increasing the range of therapeutics and eventually, boosting the global epilepsy with myoclonic atonic seizures therapeutics market.
Strategic partnership among the key players is leading to the advancements in the therapeutics. Moreover, the pipeline drugs, if approved, are expected to generate a large revenue share, spurring to the epilepsy with myoclonic atonic seizures therapeutics market.
Existing Restraints
Availability of limited treatment option hinders the global epilepsy with myoclonic atonic seizures therapeutics market. Moreover, the high costs of medication are expected to constrain the market in term of revenue share during the forecast period. Furthermore, numerous side effects associated with the drugs are also anticipated to limit the market for epilepsy with myoclonic atonic seizures therapeutics during the forecast period. Additionally, the inaccessibility of advanced healthcare facilities in the remote areas are projected to restrain the EMAS therapeutics market during the projection period.
Emerging Opportunities
Research and developmental activities in the field of myoclonic atonic seizures (MAS) therapeutics market for novel drug development include targeting specific ion channels involved in MAS generation, exploring neurosteroids to reduce seizure frequency & severity, gene therapy to modify faulty genes, and developing drugs to modulate the immune response.
Precision medicine and biomarkers help identify biomarkers and genetic mutations associated with MAS susceptibility. Electrophysiological studies map brain activity and identify specific circuits involved in MAS generation, enabling targeted interventions, offering growth opportunities in the market.
Stimulation therapies include deep brain stimulation (DBS), repetitive transcranial magnetic stimulation (rTMS), and closed-loop systems that detect and respond to seizure onset in real-time for immediate intervention. Non-pharmacological approaches include dietary interventions, cognitive-behavioral therapy (CBT), and physical therapy to improve balance and coordination.
Improvements in the dietary intervention aims to make a clinical impact on the patient health status and outcome by planning a strategic and tailored patient specific nutritional need. Dietary intervention is Investing in research, exploring novel approaches, and addressing challenges, is expected to provide a quality life to the patients and seizure control, boosting the market.
Scope of the Epilepsy with Myoclonic Atonic Seizures Therapeutics Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.
|
Attributes |
Details |
|
Report Title |
Epilepsy With Myoclonic Atonic Seizures Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2023 |
|
Historic Data |
2017 -2022 |
|
Forecast Period |
2024–2032 |
|
Segmentation |
Drug (Sodium Valproate and Levetiracetam), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
AbbVie Inc.; Eisai Co., Ltd.; GlaxoSmithKline PLC; H. Lundbeck A/S; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals Plc; Pfizer Inc.; Sanofi S.A.; Sun Pharmaceuticals Industries Ltd.; Takeda Pharmaceutical Company Limited; and UCB Pharmaceuticals Inc. |
Epilepsy with Myoclonic Atonic Seizures Therapeutics Market Segment Insights
Drug Segment Analysis
Based on drug, the epilepsy with myoclonic atonic seizures therapeutics market is divided into sodium valproate and levetiracetam. The levetiracetam segment held a major share of the market in 2023, owing to its broad-spectrum effectivity against epilepsy with myoclonic atonic seizures. Levetiracetam has comparatively lesser side effects as compared to other antiepileptic drugs, making it a preferable option for epilepsy with myoclonic atonic seizures patients, driving the segment.
The generic formulation of levetiracetam, used as a monotherapy of adjunctive therapy results in positive patient response. The treatment is currently largely being used by the patients and is expected to continually be prescribed by the doctors in the coming years, boosting the segment.
Distribution Channel Segment Analysis
On the basis of distribution channel, the global epilepsy with myoclonic atonic seizures therapeutics market is segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment held largest market share in 2023, due to the patients suffering from epilepsy with myoclonic atonic seizures getting admitted to hospital for medical interventions and timely check-ups. The patients suffering from such epilepsy seizures are usually critical and require close monitoring & prescribed changes in dosage of medication. Hospital pharmacy provides a transitional care from the start of the seizure episode till they get discharged from the hospitals, thus propelling the segment.
Regional Outlook
In terms of region, the global epilepsy with myoclonic atonic seizures therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. North America held a major market share in 2023, due to large patient pool suffering from epilepsy with myoclonic atonic seizures in the region. According to reports, almost 3.8 million population of North America are suffering from epilepsy with myoclonic-atonic seizures. The top notch infrastructure, advanced diagnostic facilities, and active participation of researchers for the novel therapeutics development drive the market in the region. Moreover, the presence of major key players in this region leads to the latest developments and maximum clinical trials of the pipeline drugs, boosting the market in North America.
The market in Asia Pacific is projected to expand at a significant pace in the coming years, owing to a large population in this region. The development in the quality of research and healthcare is expected to boost the market significantly during the forecast period. Additionally, the awareness among population for immediate disease diagnosis and treatment is anticipated to drive the epilepsy with myoclonic-atonic seizures therapeutics market during the projection period.
Segments
The epilepsy with myoclonic atonic seizures therapeutics market has been segmented on the basis of
Drug
- Sodium Valproate
- Levetiracetam
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- AbbVie Inc.
- Eisai Co., Ltd.
- GlaxoSmithKline PLC
- H. Lundbeck A/S
- Janssen Pharmaceuticals, Inc.
- Jazz Pharmaceuticals Plc
- Pfizer Inc.
- Sanofi S.A.
- Sun Pharmaceuticals Industries Ltd.
- Takeda Pharmaceutical Company Limited
- UCB Pharmaceuticals Inc.
Competitive Landscape
Key players competing in the global epilepsy with myoclonic atonic seizures therapeutics market are AbbVie Inc.; Eisai Co., Ltd.; GlaxoSmithKline PLC; H. Lundbeck A/S; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals Plc; Pfizer Inc.; Sanofi S.A.; Sun Pharmaceuticals Industries Ltd.; Takeda Pharmaceutical Company Limited; and UCB Pharmaceuticals Inc.
These companies use development strategies including mergers, acquisitions, partnerships, collaboration, and product launches to expand their consumer base globally.
-
On April 26, 2023, University of Saskatchewan started a clinical trial on Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E). This research is evaluated in a small group of children with refractory epileptic encephalopathy the safety and tolerability of a cannabis herbal extract enhanced with cannabidiol. The dosage of cannabis herbal extract is gradually increased over a four-month time period. The study is currently in the clinical trail phase-1 stage. If approved, this medicine can be used in treating the associated disorders of EMAS.
-
In August 2022, Jazz Pharmaceuticals plc started a fresh phase-3 trial has been to examine the safety and effectiveness of Epidiolex, which is marketed as Epidyolex in Europe, in treating children and teenagers with epilepsy who have myoclonic-atonic seizures (EMAS). During the course of the 14-week treatment period, the randomized, double-blind, and placebo-controlled study examined the frequency of EMAS-associated seizures in comparison to baseline.
-
In January 2022, UCB acquired Zogenix for USD 1.9 billion, adding a licensed drug Fintepla (fenfluramine), to treat Dravet syndrome, a rare form of pediatric epilepsy, and seizures associated with it.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Epilepsy With Myoclonic Atonic Seizures Therapeutics Market - Supply Chain
4.5. Global Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Forecast
4.5.1. Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Absolute $ Opportunity
5. Global Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Types
5.3.1. Types
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Applications
6.3.1. Applications
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Analysis and Forecast by End Users
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by End Users
7.2.2. Y-o-Y Growth Projections by End Users
7.3. Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by End Users
7.3.1. End Users
7.4. Absolute $ Opportunity Assessment by End Users
7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Epilepsy With Myoclonic Atonic Seizures Therapeutics Demand Share Forecast, 2019-2026
9. North America Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Types
9.4.1. Types
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. North America Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Applications
9.7.1. Applications
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. North America Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by End Users
9.10.1. End Users
9.11. Basis Point Share (BPS) Analysis by End Users
9.12. Y-o-Y Growth Projections by End Users
9.13. Market Attractiveness/Growth Potential Analysis
9.13.1. By Country
9.13.2. By Product Type
9.13.3. By Application
9.14. North America Epilepsy With Myoclonic Atonic Seizures Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Types
10.4.1. Types
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Latin America Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Applications
10.7.1. Applications
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Latin America Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by End Users
10.10.1. End Users
10.11. Basis Point Share (BPS) Analysis by End Users
10.12. Y-o-Y Growth Projections by End Users
10.13. Market Attractiveness/Growth Potential Analysis
10.13.1. By Country
10.13.2. By Product Type
10.13.3. By Application
10.14. Latin America Epilepsy With Myoclonic Atonic Seizures Therapeutics Demand Share Forecast, 2019-2026
11. Europe Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Types
11.4.1. Types
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Europe Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Applications
11.7.1. Applications
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Europe Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by End Users
11.10.1. End Users
11.11. Basis Point Share (BPS) Analysis by End Users
11.12. Y-o-Y Growth Projections by End Users
11.13. Market Attractiveness/Growth Potential Analysis
11.13.1. By Country
11.13.2. By Product Type
11.13.3. By Application
11.14. Europe Epilepsy With Myoclonic Atonic Seizures Therapeutics Demand Share Forecast, 2019-2026
12. Asia Pacific Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Types
12.4.1. Types
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Asia Pacific Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Applications
12.7.1. Applications
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Asia Pacific Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by End Users
12.10.1. End Users
12.11. Basis Point Share (BPS) Analysis by End Users
12.12. Y-o-Y Growth Projections by End Users
12.13. Market Attractiveness/Growth Potential Analysis
12.13.1. By Country
12.13.2. By Product Type
12.13.3. By Application
12.14. Asia Pacific Epilepsy With Myoclonic Atonic Seizures Therapeutics Demand Share Forecast, 2019-2026
13. Middle East & Africa Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Middle East & Africa Average Pricing Analysis
13.2. Middle East & Africa Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Types
13.4.1. Types
13.5. Basis Point Share (BPS) Analysis by Types
13.6. Y-o-Y Growth Projections by Types
13.7. Middle East & Africa Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by Applications
13.7.1. Applications
13.8. Basis Point Share (BPS) Analysis by Applications
13.9. Y-o-Y Growth Projections by Applications
13.10. Middle East & Africa Epilepsy With Myoclonic Atonic Seizures Therapeutics Market Size and Volume Forecast by End Users
13.10.1. End Users
13.11. Basis Point Share (BPS) Analysis by End Users
13.12. Y-o-Y Growth Projections by End Users
13.13. Market Attractiveness/Growth Potential Analysis
13.13.1. By Country
13.13.2. By Product Type
13.13.3. By Application
13.14. Middle East & Africa Epilepsy With Myoclonic Atonic Seizures Therapeutics Demand Share Forecast, 2019-2026
14. Competition Landscape
14.1. Global Epilepsy With Myoclonic Atonic Seizures Therapeutics Market: Market Share Analysis
14.2. Epilepsy With Myoclonic Atonic Seizures Therapeutics Distributors and Customers
14.3. Epilepsy With Myoclonic Atonic Seizures Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
14.4.1. Major Players
Methodology
Related Reports
Some other reports from this category!
Our Clients
